New developments in obsessive-compulsive disorder research: Implications for clinical management

Y. Sasson, J. Zohar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Over the past decade, epidemiological, phenomenological, pharmacological, neurobiological, brain imaging and genetic research has contributed to a substantial change in our understanding of obsessive-compulsive disorder (OCD). Once regarded as a rare psychodynamic illness, OCD is now recognized as a common condition affecting 2-3% of the population. Better recognition combined with the demonstrated efficacy of serotonin reuptake inhibitors, such as clomipraimne and the selective serotonin reuptake inhibitors (SSRIs), has dramatically improved the prognosis of this disorder, which exacts a considerable personal and economic burden. While the aetiology is still not understood, increasingly sophisticated research techniques are enabling us to begin to uncover the underlying pathophysiology of this illness. This paper reviews some of the recent developments which have enhanced our understanding of OCD and considers their potential impact on clinical management.

Original languageEnglish
Pages (from-to)3-12
Number of pages10
JournalInternational Clinical Psychopharmacology
Issue numberSUPPL. 5
StatePublished - 1996


  • 5-hydroxytryptamine
  • dopamine
  • genetics
  • obsessive-compulsive disorder
  • pathogenesis


Dive into the research topics of 'New developments in obsessive-compulsive disorder research: Implications for clinical management'. Together they form a unique fingerprint.

Cite this